GlassScriptPhysician profile
Jeffrey T Shaver
NPI 1073582409
$10,670.61
in general payments reported to CMS, 2019-2025
30 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,668 · 2020: $1,172 · 2021: $851 · 2022: $1,372 · 2023: $1,326 · 2024: $1,667 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,608.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,791.02 | 2019-2025 | Idose, Idosetr, Istent Infinite |
| Alcon Vision LLC | $1,328.33 | 2019-2025 | Clareon Panoptix Pro, Clareon, Argos |
| Bausch & Lomb Americas INC. | $1,249.07 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Abbvie INC. | $719.66 | 2022-2025 | Durysta, Vuity, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $695.53 | 2019-2020 | |
| Harrow Eye, LLC | $572.88 | 2023-2025 | Vevye |
| Amgen INC. | $443.22 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $357.77 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $331.77 | 2019-2024 | Cequa |
| Allergan, INC. | $298.35 | 2019-2020 | |
| Dompe US, INC. | $283.51 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $226.88 | 2022-2025 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $179.89 | 2022-2023 | Tepezza |
| Omeros Corporation | $169.01 | 2019 | |
| Ivantis, INC | $163.12 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $142.43 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $103.47 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Aerie Pharmaceuticals, INC. | $101.67 | 2020 | |
| Sight Sciences, INC. | $79.48 | 2021-2022 | |
| Ocular Therapeutix, INC. | $75.59 | 2021-2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $58.75 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $58.03 | 2025 | Xdemvy |
| New World Medical,INC. | $57.04 | 2019 | |
| Shire North American Group INC | $56.97 | 2019 | |
| Apellis Pharmaceuticals, INC. | $36.61 | 2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $27.81 | 2019-2021 | |
| The Cameron-Ehlen Group, INC. | $24.16 | 2019 | |
| Tearlab Corp | $17.18 | 2024 | Scoutpro Osmolarity System |
| Eyepoint US, INC. | $11.66 | 2019 | |
| Katena Products, INC. (Dba Corza Medical) | $9.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.